为便于广大投资者进一步了解公司经营情况及未来发展规划，公司定于 2025 年 5 月 16 日（星期五）15:00-17:00 在深圳证券交易所"互动易"平台"云 访谈"栏目举行 2024 年度网上业绩说明会（以下简称"本次说明会"）。本次 说明会将采用网络远程的方式举行，投资者可登陆深圳证券交易所"互动易"平 台（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次说明会。 出席本次说明会的人员有：公司董事长、总经理余养朝先生，董事、董事会 秘书、财务负责人钱韬先生，独立董事刘芝玉先生，保荐代表人韩昆仑先生。（如 有特殊情况，参会人员将有可能进行调整） 证券代码：300970 证券简称：华绿生物 公告编号：2025-022 江苏华绿生物科技集团股份有限公司 关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 江苏华绿生物科技集团股份有限公司（以下简称"公司"）《2024 年年度 报告》全文及其摘要已于 2025 年 4 月 24 日披露于中国证监会指定的创业板信息 披露网站巨潮资讯网（ht ...

证券代码：300970 证券简称：华绿生物 公告编号：2025-021 江苏华绿生物科技集团股份有限公司 关于召开 2024 年年度股东大会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 江苏华绿生物科技集团股份有限公司（以下简称"公司"）第五届董事会第 十三次会议审议通过了《关于提请召开公司 2024 年年度股东大会的议案》，决 定于 2025 年 5 月 20 日（星期二）召开公司 2024 年年度股东大会，现将本次股 东大会的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召集和召开符合《中华人民 共和国公司法》《上市公司股东大会规则》等法律、行政法规、部门规章、规范 性文件及《公司章程》《股东大会议事规则》的有关规定。 4、会议召开的日期、时间： （1）现场会议时间：2025 年 5 月 20 日（星期二）14:30。 （2）网络投票时间：2025 年 5 月 20 日（星期二）。 其中，通过深圳证券交易所交易系统进行网络投 ...

证券代码：300970 证券简称：华绿生物 公告编号：2025-012 江苏华绿生物科技集团股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会召开情况 江苏华绿生物科技集团股份有限公司（以下简称"公司"）第五届监事会第 十一次会议于 2025 年 4 月 23 日以现场和通讯相结合的方式在公司二楼会议室 召开，会议通知于 2025 年 4 月 15 日以通讯方式向全体监事送达。会议应出席监 事 3 人，实际出席监事 3 人。公司董事会秘书列席了本次会议，会议由监事会主 席李贺文先生主持。本次监事会的召开符合《中华人民共和国公司法》等有关法 律、行政法规等规范性文件及《公司章程》的规定。 二、监事会审议情况 经与会监事认真审议，形成如下决议： （三）审议通过了《关于<公司 2024 年度财务决算报告>的议案》 （一）审议通过了《关于<公司 2024 年度监事会工作报告>的议案》 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《2024 年 度监事会工作报告》。 表决结果：赞成 ...

证券代码：300970 证券简称：华绿生物 公告编号：2025-011 二、董事会审议情况 经与会董事认真审议，形成如下决议： （一）审议通过了《关于<公司 2024 年度总经理工作报告>的议案》 经审核，董事会认为：2024 年度公司以总经理为代表的管理层有效地执行 了董事会的各项决议，该报告客观、真实地反映了管理层 2024 年度主要工作。 表决结果：赞成 9 票，反对 0 票，弃权 0 票。 （二）审议通过了《关于<公司 2024 年度董事会工作报告>的议案》 公司独立董事张英明先生、刘芝玉先生及杨焱女士分别向董事会递交了 《2024 年度独立董事述职报告》，并将在公司 2024 年年度股东大会上述职。 江苏华绿生物科技集团股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会召开情况 江苏华绿生物科技集团股份有限公司（以下简称"公司"）第五届董事会第 十三次会议于 2025 年 4 月 23 日以现场和通讯相结合的方式在公司二楼会议室召 开，会议通知于 2025 年 4 月 15 日以通讯方式向全体 ...

证券代码：300970 证券简称：华绿生物 公告编号：2025-014 江苏华绿生物科技集团股份有限公司 关于 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 江苏华绿生物科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第五届董事会第十三次会议及第五届监事会第十一次会议，分别审议 通过了《关于 2024 年度拟不进行利润分配的议案》，本议案尚需提交公司 2024 年年度股东大会审议。现将具体情况公告如下： 一、2024 年度利润分配预案基本情况 经致同会计师事务所（特殊普通合伙）审计，并出具标准无保留意见的《2024 年度审计报告》确认，公司 2024 年度合并报表归属于上市公司股东的净利润为 -47,565,525.06 元，2024 年度母公司的净利润为 263,908,344.09 元。截至 2024 年 12 月 31 日，合并报表归属于上市公司股东的累计未分配利润为 437,710,562.97 元，母公司累计未分配利润为 238,102,442.44 元。 依照《公司法》《上 ...

Financial Performance - The company reported a basic earnings per share of -0.4100 yuan for 2024, a decrease of 257.69% compared to 0.2600 yuan in 2023 [1] - The net profit for 2024 was -0.48 billion yuan, reflecting a significant decline of 260% from 0.3 billion yuan in 2023 [1] - The return on equity (ROE) dropped to -3.19% in 2024, down from 1.98% in 2023, indicating a decline of 261.11% [1] - Operating revenue increased to 10.32 billion yuan in 2024, a growth of 3.61% from 9.96 billion yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 25.3355 million shares, accounting for 27.33% of the circulating shares, which is a decrease of 2.2876 million shares from the previous period [1] - The largest shareholder, 阮秀莲, holds 9.6839 million shares, representing 10.44% of the total share capital, with no change in holdings [2] - 江苏高投发展创业投资有限公司 reduced its holdings by 697.8 thousand shares, now holding 5.6176 million shares, which is 6.06% of the total [2] Dividend Policy - The company has announced no distribution or capital increase for the current period [1]

Financial Performance - The company reported a net profit attributable to shareholders of -47,565,525.06 RMB for the year 2024, a decrease of 256.73% compared to 2023[3]. - The decline in net profit was primarily due to a significant drop in the sales price of the main product, enoki mushrooms, influenced by market conditions in the vegetable and edible mushroom sectors[3]. - The company's operating revenue for 2024 was ¥1,032,111,560.17, representing a 3.60% increase compared to ¥996,221,375.81 in 2023[19]. - The net profit attributable to shareholders for 2024 was -¥47,565,525.06, a decrease of 256.73% from ¥30,348,940.26 in 2023[19]. - The net cash flow from operating activities decreased by 17.32% to ¥137,798,307.93 in 2024 from ¥166,672,655.98 in 2023[19]. - The total assets at the end of 2024 increased by 8.80% to ¥2,305,515,184.73 compared to ¥2,118,970,407.99 at the end of 2023[19]. - The weighted average return on equity for 2024 was -3.19%, down from 1.98% in 2023, indicating a significant decline in profitability[19]. - The company reported a basic earnings per share of -¥0.41 for 2024, a decrease of 257.69% from ¥0.26 in 2023[19]. - The gross profit margin for edible mushrooms decreased by 7.56% to 5.96%[59]. Revenue and Sales - The company achieved a sales volume of 230,000 tons during the reporting period, representing a year-on-year increase of 21.28%[52]. - The total sales revenue reached 1,032,111,560.17 CNY, marking the first time it surpassed the 1 billion CNY threshold, with a year-on-year growth of 3.60%[56]. - The company’s main product, enoki mushrooms, generated revenue of 713,752,000.76 CNY, accounting for 69.15% of total sales, with a growth of 1.80% compared to the previous year[56]. - The company reported a significant increase in revenue from the "Others" category, which rose by 157.09% to ¥15,498,664.89[59]. Costs and Expenses - Cumulative expenses of approximately 20 million RMB were recognized due to the implementation of the 2022/2023 incentive plan, contributing to the overall decline in gross profit margin[3]. - The total cost of sales increased by 12.48% to ¥972,796,670.86, with direct raw materials accounting for 37.23% of total costs[63]. - The company experienced increased depreciation expenses due to the completion and capitalization of certain projects during the reporting period[3]. - The company’s financial expenses surged by 5,707.10% to ¥7,939,015.98, primarily due to increased lease liability interest expenses[67]. Strategic Plans and Market Position - The company plans to complete and put into operation its facilities in Henan and Guangxi in the second half of 2024, which is expected to drive revenue growth[42]. - The company is facing challenges due to increased competition and market fluctuations, necessitating strategic adjustments to maintain its market position[31]. - The company aims to enhance production levels at existing bases and deepen the national sales network, focusing on a multi-variety strategy for mushroom production[85]. - By 2025, the company plans to consolidate its leading position in the mushroom industry and expand its product line, particularly in factory-cultivated mushrooms and processed products[86]. Research and Development - The company invested over 14.6 million CNY in R&D, resulting in the addition of 21 new patents, enhancing its technological strength and intellectual property protection[53]. - The R&D team is composed of experienced professionals from agriculture, food, and biology, supporting the company's innovation efforts[41]. - The company has signed contracts for hybrid breeding of new strains of yellow enoki mushrooms, aiming to develop 1-2 patented strains suitable for industrial cultivation[68]. - The company will continue to invest in R&D to improve technology levels and increase biological conversion rates and yield per bottle in mushroom cultivation[87]. Governance and Compliance - The company has established a comprehensive internal control system to ensure product traceability and minimize food safety risks[91]. - The board of directors consists of 9 members, including 3 independent directors, and operates in accordance with relevant laws and regulations[98]. - The company has established an independent financial management department, ensuring autonomous financial decision-making and compliance with accounting standards[103]. - The company has implemented a robust investor relations management system, enhancing communication and transparency with investors[100]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating compliance with environmental regulations[150]. - The company has adhered to multiple environmental protection laws and standards, ensuring all construction projects meet environmental impact assessment requirements[152]. - The company has implemented a wastewater treatment system that adheres to the principle of "separation of clean and dirty water," ensuring that treated wastewater meets discharge standards before being used for landscaping[155]. - The company has established an environmental self-monitoring plan, with automatic monitoring devices installed to ensure compliance with relevant emission standards[156]. Social Responsibility - The company aims to provide more job opportunities for disadvantaged groups, continuing to support poverty alleviation and rural revitalization efforts[164]. - The establishment of a "mushroom bottling workshop" in Chongqing has created a demonstration workshop for employment assistance, successfully absorbing local impoverished labor[163]. - The company emphasizes the importance of connecting poverty alleviation results with rural revitalization, enhancing local economic self-sufficiency[163]. - The company has committed to fulfilling its social responsibilities by stabilizing and expanding employment positions, linking upstream and downstream industries[163]. Shareholder Relations - The company has a clear strategy for managing share transfers and reductions to ensure compliance with legal requirements[173]. - The company will ensure compliance with all relevant laws and regulations regarding share transactions and investor protection[177]. - The company will compensate investors for direct losses incurred due to reliance on commitments that were not fulfilled[181]. - The company actively protects shareholder rights by adhering to legal requirements for timely and accurate information disclosure, enhancing transparency through various communication channels[158].

Financial Performance - The company's revenue for Q1 2025 was ¥270,596,190.27, representing a 5.33% increase compared to ¥256,905,255.97 in the same period last year[4] - Net profit attributable to shareholders decreased by 11.20% to ¥1,544,654.24 from ¥1,739,546.28 year-on-year[4] - The net profit after deducting non-recurring gains and losses increased by 38.07% to ¥1,128,975.92 from ¥817,696.94 in the previous year[4] - Total operating revenue for the current period reached ¥270,596,190.27, an increase of 5.3% compared to ¥256,905,255.97 in the previous period[18] - Net profit for the current period was ¥1,964,285.37, a decrease of 19.1% from ¥2,427,205.96 in the previous period[19] Cash Flow and Assets - The net cash flow from operating activities rose by 9.67% to ¥39,057,383.54 compared to ¥35,613,948.24 in the same period last year[4] - The net cash flow from operating activities was ¥39,057,383.54, compared to ¥35,613,948.24 in the previous period, indicating an increase of 6.8%[20] - The company reported a net cash flow from investing activities of -¥36,008,467.83, an improvement from -¥50,383,705.09 in the previous period[22] - Cash and cash equivalents at the end of the period totaled ¥370,068,084.65, up from ¥336,898,188.19 at the end of the previous period[22] - The company's total assets reached ¥2,307,326,846.86, compared to ¥2,305,515,184.73 in the previous period, showing a slight increase[16] Shareholder Information - The company reported a total of 10,189 common shareholders at the end of the reporting period[8] - The largest shareholder, Yu Yangchao, holds 30.27% of the shares, totaling 36,387,628 shares[9] - The company plans to repurchase shares using between RMB 30 million and RMB 60 million, with a total of 2,346,600 shares repurchased, accounting for 1.99% of the total share capital[12] - The company has completed the share repurchase plan as of the reporting period[12] - The company aims to enhance investor confidence and align interests through the share repurchase program[12] Equity and Liabilities - Total assets at the end of the reporting period were ¥2,307,326,846.86, a slight increase of 0.08% from ¥2,305,515,184.73 at the end of the previous year[4] - Shareholders' equity attributable to the parent company increased by 0.29% to ¥1,496,358,459.85 from ¥1,492,022,748.07 at the end of the previous year[4] - The company's total liabilities were RMB 783,179,491.98, slightly down from RMB 786,123,172.76 at the beginning of the period[15] - The equity attributable to shareholders of the parent company was ¥1,496,358,459.85, up from ¥1,492,022,748.07, reflecting a growth of 0.2%[16] Earnings Per Share - The basic earnings per share decreased by 50.00% to ¥0.01 from ¥0.02 in the same period last year[4] - Basic and diluted earnings per share for the current period were both ¥0.01, down from ¥0.02 in the previous period[20] Operating Costs - Total operating costs amounted to ¥271,307,730.48, up from ¥257,780,429.22, reflecting a rise of 5.2%[18] Asset Composition - The company's current assets totaled RMB 602,163,314.71, up from RMB 579,976,110.79 at the beginning of the period[13] - The company's non-current assets decreased from RMB 1,725,539,073.94 to RMB 1,705,163,532.15 during the same period[13] - The company's cash and cash equivalents increased to RMB 373,324,620.90 from RMB 361,137,972.25[13] - Accounts receivable rose to RMB 20,004,757.55 from RMB 16,696,728.60, indicating a growth in receivables[13]

江苏华绿生物科技集团股份有限公司 二〇二四年度 审计报告 致同会计师事务所（特殊普通合伙） 目 录 | 审计报告 | 1-5 | | --- | --- | | 合并及公司资产负债表 | 1-2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-84 | 致同会计师事务所（特殊普通合伙） 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 一、审计意见 我们审计了江苏华绿生物科技集团股份有限公司（以下简称华绿生物公 司）财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度 的合并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表 以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了华绿生物公司 2024 年 12 月 31 日的合并及公司财务状况以及 2024 年度的合并及公司经 ...

致同会计师事务所（特殊普通合伙） 目 录 专项核查报告 公司 2024 年度营业收入扣除情况表及说明 1-3 江苏华绿生物科技集团股份有限公司 营业收入扣除情况表 专项核查报告 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 江苏华绿生物科技集团股份有限公司 营业收入扣除情况表专项核查报告 致同专字（2025）第 371A009355 号 江苏华绿生物科技集团股份有限公司全体股东： 我们接受委托，在审计了江苏华绿生物科技集团股份有限公司（以下简 称"华绿生物公司"）2024 年 12 月 31 日的合并及公司资产负债表，2024 年度 的合并及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表 以及财务报表附注的基础上，对后附的《华绿生物公司 2024 年度营业收入扣 除情况表及说明》（以下简称"营业收入扣除情况表"）进行了专项核查。 按照《深圳证券交易所股票上市规则》、《深圳证券交易所创业板股票 上市规则》（以下简称 ...